Borrow it
Coverart for item
The Resource Bad blood : secrets and lies in a Silicon Valley startup, John Carreyrou

Bad blood : secrets and lies in a Silicon Valley startup, John Carreyrou

Creator
Summary
  • "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
  • "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
Language
eng
Work
Publication
Edition
First edition.
Extent
x, 339 pages
Contents
  • A purposeful life
  • The gluebot
  • Apple envy
  • Goodbye East Paly
  • The childhood neighbor
  • Sunny
  • Dr. J
  • The miniLab
  • The wellness play
  • "Who is LTC Shoemaker?"
  • Lighting a Fuisz
  • Ian Gibbons
  • Chiat\day
  • Going live
  • Unicorn
  • The grandson
  • Fame
  • The hippocratic oath
  • The tip
  • The ambush
  • Trade secrets
  • La mattanza
  • Damage control
  • The empress has no clothes
  • Epilogue
Isbn
9781524731656
Instance
Label
Bad blood : secrets and lies in a Silicon Valley startup
Title
Bad blood
Title remainder
secrets and lies in a Silicon Valley startup
Statement of responsibility
John Carreyrou
Creator
Subject
Genre
Language
eng
Summary
  • "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
  • "The full inside story of the breathtaking rise and shocking collapse of Theranos--the Enron of Silicon Valley--by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in an early fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at the Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
Assigning source
  • Provided by publisher
  • Provided by publisher
Cataloging source
DLC
http://library.link/vocab/creatorName
Carreyrou, John
Dewey number
338.7/681761
Index
index present
LC call number
HD9995.H423
LC item number
U627 2018
Literary form
non fiction
Nature of contents
bibliography
http://library.link/vocab/subjectName
  • Theranos (Firm)
  • Hematologic equipment industry
  • Fraud
  • New business enterprises
  • BUSINESS & ECONOMICS / Entrepreneurship
  • BUSINESS & ECONOMICS / Finance
  • TECHNOLOGY & ENGINEERING / Biomedical
  • Fraud
  • Hematologic equipment industry
  • United States
  • BUSINESS & ECONOMICS / Entrepreneurship
  • BUSINESS & ECONOMICS / Finance
  • TECHNOLOGY & ENGINEERING / Biomedical
  • BUSINESS & ECONOMICS / Finance / General
Label
Bad blood : secrets and lies in a Silicon Valley startup, John Carreyrou
Instantiates
Publication
Copyright
Bibliography note
Includes bibliographical references and index
Carrier category
volume
Carrier category code
  • nc
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\day -- Going live -- Unicorn -- The grandson -- Fame -- The hippocratic oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue
Control code
on1029779381
Dimensions
25 cm
Edition
First edition.
Extent
x, 339 pages
Isbn
9781524731656
Lccn
2018000263
Media category
unmediated
Media MARC source
rdamedia
Media type code
  • n
System control number
  • (Sirsi) o1029779381
  • (OCoLC)1029779381
Label
Bad blood : secrets and lies in a Silicon Valley startup, John Carreyrou
Publication
Copyright
Bibliography note
Includes bibliographical references and index
Carrier category
volume
Carrier category code
  • nc
Carrier MARC source
rdacarrier
Content category
text
Content type code
  • txt
Content type MARC source
rdacontent
Contents
A purposeful life -- The gluebot -- Apple envy -- Goodbye East Paly -- The childhood neighbor -- Sunny -- Dr. J -- The miniLab -- The wellness play -- "Who is LTC Shoemaker?" -- Lighting a Fuisz -- Ian Gibbons -- Chiat\day -- Going live -- Unicorn -- The grandson -- Fame -- The hippocratic oath -- The tip -- The ambush -- Trade secrets -- La mattanza -- Damage control -- The empress has no clothes -- Epilogue
Control code
on1029779381
Dimensions
25 cm
Edition
First edition.
Extent
x, 339 pages
Isbn
9781524731656
Lccn
2018000263
Media category
unmediated
Media MARC source
rdamedia
Media type code
  • n
System control number
  • (Sirsi) o1029779381
  • (OCoLC)1029779381

Subject

Genre

Included in

Library Locations

    • Fairfield Lane LibraryBorrow it
      1485 Corydale Dr, Fairfield, OH, 45014, US
      39.3346902 -84.5657102
    • Oxford Lane LibraryBorrow it
      441 S Locust St, Oxford, OH, 45056, US
      39.5055538 -84.74835399999999

Library Links

Structured data from the Bibframe namespace is licensed under the Creative Commons Attribution 4.0 International License by Lane Public Library. Additional terms may apply to data associated with third party namespaces.
Processing Feedback ...